Krishnansu Sujata Tewari

Title(s)Professor, Obstetrics and Gynecology
Address1001 Health Sciences Road
Irvine CA 92697-3950
Phone(714) 456-7971
vCardDownload vCard

    Collapse Research 
    Collapse Research Activities and Funding
    Novel biologic markers of treatment resistance in locally advanced cervical carci
    NIH R21CA156032Jan 1, 2011 - Dec 31, 2015
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Beyond Sedlis-A novel histology-specific nomogram for predicting cervical cancer recurrence risk: An NRG/GOG ancillary analysis. Gynecol Oncol. 2021 Jun 30. Levinson K, Beavis AL, Purdy C, Rositch AF, Viswanathan A, Wolfson AH, Kelly MG, Tewari KS, McNally L, Guntupalli SR, Ragab O, Lee YC, Miller DS, Huh WK, Wilkinson KJ, Spirtos NM, Van Le L, Casablanca Y, Holman LL, Waggoner SE, Fader AN. PMID: 34217544.
      View in: PubMed   Mentions:    Fields:    
    2. Lung cancer diagnosed on pap smear: A case report and review of the literature. Gynecol Oncol Rep. 2021 May; 36:100776. Leaf MC, Pearre D, Cappuccini F, Tewari K. PMID: 34026999.
      View in: PubMed   Mentions:
    3. Should adjuvant chemotherapy be formally studied among patients found to have pelvic lymph node metastases following radical hysterectomy with lymphadenectomy for early-stage cervical cancer? J Gynecol Oncol. 2021 Apr 19. Bujnak AC, Tewari KS. PMID: 33908714.
      View in: PubMed   Mentions:    Fields:    
    4. Niraparib in the maintenance treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: safety and efficacy. Expert Rev Anticancer Ther. 2021 Mar 11; 1-6. Liu MC, Sutedja J, Tewari KS. PMID: 33691564.
      View in: PubMed   Mentions:    Fields:    
    5. Correlation of imaging and plasma based biomarkers to predict response to bevacizumab in epithelial ovarian cancer (EOC). Gynecol Oncol. 2021 Mar 09. Buechel ME, Enserro D, Burger RA, Brady MF, Wade K, Secord AA, Nixon AB, Mirniaharikandehei S, Liu H, Zheng B, O'Malley DM, Gray H, Tewari KS, Mannel RS, Birrer MJ, Moore KN. PMID: 33712274.
      View in: PubMed   Mentions:    Fields:    
    6. Utilizing an interim futility analysis of the OVAL study (VB-111-701/GOG 3018) for potential reduction of risk: A phase III, double blind, randomized controlled trial of ofranergene obadenovec (VB-111) and weekly paclitaxel in patients with platinum resistant ovarian cancer. Gynecol Oncol. 2021 May; 161(2):496-501. Arend RC, Monk BJ, Herzog TJ, Moore KN, Shapira-Frommer R, Ledermann JA, Tewari KS, Secord AA, Rachmilewitz Minei T, Freedman LS, Miller A, Shmueli SF, Lavi M, Penson RT. PMID: 33637348.
      View in: PubMed   Mentions:    Fields:    
    7. Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study. Gynecol Oncol. 2021 Apr; 161(1):113-121. Leslie KK, Filiaci VL, Mallen AR, Thiel KW, Devor EJ, Moxley K, Richardson D, Mutch D, Secord AA, Tewari KS, McDonald ME, Mathews C, Cosgrove C, Dewdney S, Casablanca Y, Jackson A, Rose PG, Zhou X, McHale M, Lankes H, Levine DA, Aghajanian C. PMID: 33541735.
      View in: PubMed   Mentions: 2     Fields:    
    8. The current landscape of molecular profiling in the treatment of epithelial ovarian cancer. Gynecol Oncol. 2021 01; 160(1):333-345. Haunschild CE, Tewari KS. PMID: 33055011.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    9. Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209). J Clin Oncol. 2020 11 20; 38(33):3841-3850. Miller DS, Filiaci VL, Mannel RS, Cohn DE, Matsumoto T, Tewari KS, DiSilvestro P, Pearl ML, Argenta PA, Powell MA, Zweizig SL, Warshal DP, Hanjani P, Carney ME, Huang H, Cella D, Zaino R, Fleming GF. PMID: 33078978.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    10. Circulating Tumor Cells In Advanced Cervical Cancer: NRG Oncology-Gynecologic Oncology Group Study 240 (NCT 00803062). Mol Cancer Ther. 2020 Aug 26. Tewari KS, Sill MW, Monk BJ, Penson RT, Moore DH, Lankes HA, Ramondetta LM, Landrum LM, Randall LM, Oaknin A, Leitao MM, Eisenhauer EL, DiSilvestro P, Van Le L, Pearl ML, Burke JJ, Salani R, Richardson DL, Michael HE, Kindelberger DW, Birrer MJ. PMID: 32847980.
      View in: PubMed   Mentions: 1     Fields:    
    11. Bevacizumab plus fosbretabulin in recurrent ovarian cancer: Overall survival and exploratory analyses of a randomized phase II NRG oncology/gynecologic oncology group study. Gynecol Oncol. 2020 10; 159(1):79-87. Tewari KS, Sill MW, Coleman RL, Aghajanian C, Mannel R, DiSilvestro PA, Powell M, Randall LM, Farley J, Rubin SC, Monk BJ. PMID: 32723679.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    12. Implementation of human papillomavirus video education for women participating in mass cervical cancer screening in Tanzania. Am J Obstet Gynecol. 2021 01; 224(1):105.e1-105.e9. Cooper EC, Maher JA, Naaseh A, Crawford EW, Chinn JO, Runge AS, Lucas AN, Zezoff DC, Bera KR, Dinicu AI, White KM, Tewari SE, Hari A, Bernstein M, Chang J, Ziogas A, Pearre DC, Tewari KS. PMID: 32682861.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    13. Robotic surgery for gynecologic cancers: indications, techniques and controversies. J Obstet Gynaecol Res. 2020 Jun; 46(6):828-843. Clair KH, Tewari KS. PMID: 32410262.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    14. Philip John DiSaia, MD: Available Light & The Origin of Storms. J Obstet Gynaecol Res. 2020 Jul; 46(7):959-988. Tewari KS, Monk BJ. PMID: 32352218.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    15. Gynecologic cancer in pregnancy. Gynecol Oncol. 2020 06; 157(3):799-809. Korenaga TK, Tewari KS. PMID: 32268951.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    16. Cost-effectiveness of niraparib, rucaparib, and olaparib for treatment of platinum-resistant, recurrent ovarian carcinoma. Gynecol Oncol. 2020 05; 157(2):500-507. Wolford JE, Bai J, Moore KN, Kristeleit R, Monk BJ, Tewari KS. PMID: 32173049.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    17. Patient-reported outcomes at discontinuation of anti-angiogenesis therapy in the randomized trial of chemotherapy with bevacizumab for advanced cervical cancer: an NRG Oncology Group study. Int J Gynecol Cancer. 2020 05; 30(5):596-601. Chase D, Huang HQ, Monk BJ, Ramondetta LM, Penson RT, Gil K, Landrum LM, Leitao M, Oaknin A, Huh WK, Pulaski HL, Robison K, Guntupalli SR, Richardson D, Salani R, Sill MW, Wenzel LB, Tewari KS. PMID: 32114513.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    18. Multimodality screening and prevention of cervical cancer in sub-Saharan Africa: a collaborative model. Curr Opin Obstet Gynecol. 2020 02; 32(1):28-35. Chinn J, Tewari KS. PMID: 31804231.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansPHPublic Health
    19. Fertility preserving treatment for gynecologic malignancies: a review of recent literature. Curr Opin Obstet Gynecol. 2020 02; 32(1):51-56. Coakley K, Wolford J, Tewari KS. PMID: 31851046.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    20. Endometrial cancer in the morbidly obese: a review. Curr Opin Obstet Gynecol. 2020 02; 32(1):42-50. Liu MC, Gardner AB, Wolford JE, Tewari KS. PMID: 31833943.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    21. Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218. Clin Cancer Res. 2020 03 15; 26(6):1288-1296. Alvarez Secord A, Bell Burdett K, Owzar K, Tritchler D, Sibley AB, Liu Y, Starr MD, Brady JC, Lankes HA, Hurwitz HI, Mannel RS, Tewari KS, O'Malley DM, Gray H, Bakkum-Gamez JN, Fujiwara K, Boente M, Deng W, Burger RA, Birrer MJ, Nixon AB. PMID: 31919136.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    22. Bevacizumab use in the frontline, maintenance and recurrent settings for ovarian cancer. Future Oncol. 2020 Mar; 16(7):225-246. Haunschild CE, Tewari KS. PMID: 31746224.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    23. Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer. N Engl J Med. 2019 11 14; 381(20):1929-1939. Coleman RL, Spirtos NM, Enserro D, Herzog TJ, Sabbatini P, Armstrong DK, Kim JW, Park SY, Kim BG, Nam JH, Fujiwara K, Walker JL, Casey AC, Alvarez Secord A, Rubin S, Chan JK, DiSilvestro P, Davidson SA, Cohn DE, Tewari KS, Basen-Engquist K, Huang HQ, Brady MF, Mannel RS. PMID: 31722153.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansCTClinical Trials
    24. Reply to Farolfi et al and Haines et al. J Clin Oncol. 2020 01 10; 38(2):173-174. Tewari KS, Monk BJ, Burger RA. PMID: 31697589.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    25. Therapeutic vaccination using HPV 16 E7 to eradicate CIN3. J Gynecol Oncol. 2019 11; 30(6):e119. Tewari KS. PMID: 31576704.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCellsPHPublic Health
    26. A phase II randomized, double-blind trial of a polyvalent Vaccine-KLH conjugate (NSC 748933 IND# 14384) + OPT-821 versus OPT-821 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer who are in second or third complete remission: An NRG Oncology/GOG study. Gynecol Oncol. 2019 12; 155(3):393-399. O'Cearbhaill RE, Deng W, Chen LM, Lucci JA, Behbakht K, Spirtos NM, Muller CY, Benigno BB, Powell MA, Berry E, Tewari KS, Hanjani P, Lankes HA, Aghajanian C, Sabbatini PJ. PMID: 31653510.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    27. Minimally Invasive Surgery for Early-Stage Cervical Carcinoma: Interpreting the Laparoscopic Approach to Cervical Cancer Trial Results. J Clin Oncol. 2019 11 20; 37(33):3075-3080. Tewari KS. PMID: 31560582.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    28. Evidence-Based Treatment Paradigms for Management of Invasive Cervical Carcinoma. J Clin Oncol. 2019 09 20; 37(27):2472-2489. Tewari KS, Monk BJ. PMID: 31403858.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    29. Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer. J Clin Oncol. 2019 09 10; 37(26):2317-2328. Tewari KS, Burger RA, Enserro D, Norquist BM, Swisher EM, Brady MF, Bookman MA, Fleming GF, Huang H, Homesley HD, Fowler JM, Greer BE, Boente M, Liang SX, Ye C, Bais C, Randall LM, Chan JK, Ferriss JS, Coleman RL, Aghajanian C, Herzog TJ, DiSaia PJ, Copeland LJ, Mannel RS, Birrer MJ, Monk BJ. PMID: 31216226.
      View in: PubMed   Mentions: 53     Fields:    Translation:HumansCTClinical Trials
    30. Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer. N Engl J Med. 2019 06 13; 380(24):2317-2326. Matei D, Filiaci V, Randall ME, Mutch D, Steinhoff MM, DiSilvestro PA, Moxley KM, Kim YM, Powell MA, O'Malley DM, Spirtos NM, Small W, Tewari KS, Richards WE, Nakayama J, Matulonis UA, Huang HQ, Miller DS. PMID: 31189035.
      View in: PubMed   Mentions: 46     Fields:    Translation:HumansCTClinical Trials
    31. Cervical cancer in Tanzania: A systematic review of current challenges in six domains. Gynecol Oncol Rep. 2019 Aug; 29:40-47. Runge AS, Bernstein ME, Lucas AN, Tewari KS. PMID: 31309135.
      View in: PubMed   Mentions:
    32. Immune Checkpoint Blockade in PD-L1-Positive Platinum-Refractory Cervical Carcinoma. J Clin Oncol. 2019 06 10; 37(17):1449-1454. Tewari KS. PMID: 31026210.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    33. Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study. J Clin Oncol. 2019 06 01; 37(16):1380-1390. Walker JL, Brady MF, Wenzel L, Fleming GF, Huang HQ, DiSilvestro PA, Fujiwara K, Alberts DS, Zheng W, Tewari KS, Cohn DE, Powell MA, Van Le L, Davidson SA, Gray HJ, Rose PG, Aghajanian C, Myers T, Alvarez Secord A, Rubin SC, Mannel RS. PMID: 31002578.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansCTClinical Trials
    34. Nomogram for Predicting Individual Survival After Recurrence of Advanced-Stage, High-Grade Ovarian Carcinoma. Obstet Gynecol. 2019 02; 133(2):245-254. Rose PG, Java JJ, Salani R, Geller MA, Secord AA, Tewari KS, Bender DP, Mutch DG, Friedlander ML, Van Le L, Method MW, Hamilton CA, Lee RB, Wenham RM, Guntupalli SR, Markman M, Muggia FM, Armstrong DK, Bookman MA, Burger RA, Copeland LJ. PMID: 30633128.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    35. Chapter 77: Ovarian Cancer. In: DeVita VT, Lawrence TS, Rosenberg SA, eds. DeVita, Hellman, and Rosenberg’s Cancer: Principles & Practice of Oncology. 2019. Tewari KS, Penson RT, and Monk BJ.
    36. Anti-angiogenesis therapy, synthetic lethality, and checkpoint inhibition in ovarian cancer: state of the science and novel combinations. Drugs Context. 2018; 7:212558. Liu MC, Tewari KS. PMID: 30627206.
      View in: PubMed   Mentions:
    37. Targeted treatment of advanced ovarian cancer: spotlight on rucaparib. Ther Clin Risk Manag. 2018; 14:2189-2201. Pearre DC, Tewari KS. PMID: 30464492.
      View in: PubMed   Mentions:
    38. Adjuvant Gemcitabine Plus Docetaxel Followed by Doxorubicin Versus Observation for High-Grade Uterine Leiomyosarcoma: A Phase III NRG Oncology/Gynecologic Oncology Group Study. J Clin Oncol. 2018 Oct 05; JCO1800454. Hensley ML, Enserro D, Hatcher H, Ottevanger PB, Krarup-Hansen A, Blay JY, Fisher C, Moxley KM, Lele SB, Lea JS, Tewari KS, Thaker PH, Zivanovic O, O'Malley DM, Robison K, Miller DS. PMID: 30289732.
      View in: PubMed   Mentions: 11     Fields:    
    39. Randomized phase II trial of bevacizumab plus everolimus versus bevacizumab alone for recurrent or persistent ovarian, fallopian tube or peritoneal carcinoma: An NRG oncology/gynecologic oncology group study. Gynecol Oncol. 2018 11; 151(2):257-263. Tew WP, Sill MW, Walker JL, Secord AA, Bonebrake AJ, Schilder JM, Stuckey A, Rice L, Tewari KS, Aghajanian CA. PMID: 30177462.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    40. Bevacizumab in Cervical Cancer: 5 Years After. Cancer J. 2018 Jul/Aug; 24(4):187-192. Pfaendler KS, Liu MC, Tewari KS. PMID: 30119082.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    41. A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer. Gynecol Oncol. 2018 08; 150(2):274-281. Aghajanian C, Filiaci V, Dizon DS, Carlson JW, Powell MA, Secord AA, Tewari KS, Bender DP, O'Malley DM, Stuckey A, Gao J, Dao F, Soslow RA, Lankes HA, Moore K, Levine DA. PMID: 29804638.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCTClinical Trials
    42. Pharmacokinetic drug evaluation of niraparib for the treatment of ovarian cancer. Expert Opin Drug Metab Toxicol. 2018 May; 14(5):543-550. Longoria TC, Tewari KS. PMID: 29620474.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimals
    43. Correlation between Surgeon's assessment and radiographic evaluation of residual disease in women with advanced stage ovarian cancer reported to have undergone optimal surgical cytoreduction: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2018 06; 149(3):525-530. Eskander RN, Kauderer J, Tewari KS, Mannel RS, Bristow RE, O'Malley DM, Rubin SC, Glaser GE, Hamilton CA, Fujiwara K, Huh WK, Ueland F, Stephan JM, Burger RA. PMID: 29550184.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    44. Oncofertility in the setting of advanced cervical cancer - A case report. Gynecol Oncol Rep. 2018 May; 24:27-29. Gordon C, Carmichael JC, Tewari KS. PMID: 29845104.
      View in: PubMed   Mentions:
    45. Rational design for cervical cancer therapeutics: cellular and non-cellular based strategies on the horizon for recurrent, metastatic or refractory cervical cancer. Expert Opin Drug Discov. 2018 05; 13(5):445-457. Wolford JE, Tewari KS. PMID: 29463131.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    46. Cervical cancer - State of the science: From angiogenesis blockade to checkpoint inhibition. Gynecol Oncol. 2018 03; 148(3):609-621. Minion LE, Tewari KS. PMID: 29666026.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    47. Clinical trial experience with CA4P anticancer therapy: focus on efficacy, cardiovascular adverse events, and hypertension management. Gynecol Oncol Res Pract. 2018; 5:1. Grisham R, Ky B, Tewari KS, Chaplin DJ, Walker J. PMID: 29318022.
      View in: PubMed   Mentions:
    48. The Ecstacy of Gold: Patent Expirations for Trastuzumab, Bevacizumab, Rituximab, and Cetuximab. Recent Pat Biotechnol. 2018; 12(2):101-112. Serna-Gallegos TR, La-Fargue CJ, Tewari KS. PMID: 29173192.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    49. Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: An NRG Oncology/Gynecologic Oncology Group Study. Clin Cancer Res. 2018 02 15; 24(4):777-783. Norquist BM, Brady MF, Harrell MI, Walsh T, Lee MK, Gulsuner S, Bernards SS, Casadei S, Burger RA, Tewari KS, Backes F, Mannel RS, Glaser G, Bailey C, Rubin S, Soper J, Lankes HA, Ramirez NC, King MC, Birrer MJ, Swisher EM. PMID: 29191972.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCells
    50. Impact of tumour histology on survival in advanced cervical carcinoma: an NRG Oncology/Gynaecologic Oncology Group Study. Br J Cancer. 2018 01; 118(2):162-170. Seamon LG, Java JJ, Monk BJ, Penson RT, Brown J, Mannel RS, Oaknin A, Leitao MM, Eisenhauer EL, Long HJ, Liao SY, Tewari KS. PMID: 29182608.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    51. Predictive modeling for determination of microscopic residual disease at primary cytoreduction: An NRG Oncology/Gynecologic Oncology Group 182 Study. Gynecol Oncol. 2018 01; 148(1):49-55. Horowitz NS, Larry Maxwell G, Miller A, Hamilton CA, Rungruang B, Rodriguez N, Richard SD, Krivak TC, Fowler JM, Mutch DG, Van Le L, Lee RB, Argenta P, Bender D, Tewari KS, Gershenson D, Java JJ, Bookman MA. PMID: 29174555.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    52. Genome-wide association study evaluating single-nucleotide polymorphisms and outcomes in patients with advanced stage serous ovarian or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2017 11; 147(2):396-401. Moore KN, Tritchler D, Kaufman KM, Lankes H, Quinn MCJ, Ovarian Cancer Association Consortium , Van Le L, Berchuck A, Backes FJ, Tewari KS, Lee RB, Kesterson JP, Wenham RM, Armstrong DK, Krivak TC, Bookman MA, Birrer MJ. PMID: 28935272.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    53. Highlights from the Gynecologic Oncology Track at the 2017 Annual Meeting of the American Society of Clinical Oncology. J Gynecol Oncol. 2017 09; 28(5):e74. Wolford JE, Tewari KS. PMID: 28758380.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    54. An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience. Gynecol Oncol. 2017 11; 147(2):243-249. Oliver KE, Brady WE, Birrer M, Gershenson DM, Fleming G, Copeland LJ, Tewari K, Argenta PA, Mannel RS, Secord AA, Stephan JM, Mutch DG, Stehman FB, Muggia FM, Rose PG, Armstrong DK, Bookman MA, Burger RA, Farley JH. PMID: 28807367.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    55. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet. 2017 Oct 07; 390(10103):1654-1663. Tewari KS, Sill MW, Penson RT, Huang H, Ramondetta LM, Landrum LM, Oaknin A, Reid TJ, Leitao MM, Michael HE, DiSaia PJ, Copeland LJ, Creasman WT, Stehman FB, Brady MF, Burger RA, Thigpen JT, Birrer MJ, Waggoner SE, Moore DH, Look KY, Koh WJ, Monk BJ. PMID: 28756902.
      View in: PubMed   Mentions: 72     Fields:    Translation:HumansCTClinical Trials
    56. A phase II evaluation of brivanib in the treatment of persistent or recurrent carcinoma of the cervix: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2017 09; 146(3):554-559. Chan JK, Deng W, Higgins RV, Tewari KS, Bonebrake AJ, Hicks M, Gaillard S, Ramirez PT, Chafe W, Monk BJ, Aghajanian C. PMID: 28728751.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    57. High stathmin expression is a marker for poor clinical outcome in endometrial cancer: An NRG oncology group/gynecologic oncology group study. Gynecol Oncol. 2017 08; 146(2):247-253. Reyes HD, Miecznikowski J, Gonzalez-Bosquet J, Devor EJ, Zhang Y, Thiel KW, Samuelson MI, McDonald M, Stephan JM, Hanjani P, Guntupalli S, Tewari KS, Backes F, Ramirez N, Fleming GF, Filiaci V, Birrer MJ, Leslie KK. PMID: 28532857.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    58. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017 06; 18(6):779-791. Coleman RL, Brady MF, Herzog TJ, Sabbatini P, Armstrong DK, Walker JL, Kim BG, Fujiwara K, Tewari KS, O'Malley DM, Davidson SA, Rubin SC, DiSilvestro P, Basen-Engquist K, Huang H, Chan JK, Spirtos NM, Ashfaq R, Mannel RS. PMID: 28438473.
      View in: PubMed   Mentions: 96     Fields:    Translation:HumansCTClinical Trials
    59. The safety and efficacy of bevacizumab in the treatment of patients with recurrent or metastatic cervical cancer. Expert Rev Anticancer Ther. 2017 Mar; 17(3):191-198. Minion LE, Tewari KS. PMID: 27748633.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimals
    60. What is the role of retroperitoneal exploration in optimally debulked stage IIIC epithelial ovarian cancer? An NRG Oncology/Gynecologic Oncology Group ancillary data study. Cancer. 2017 May 15; 123(6):985-993. Rungruang BJ, Miller A, Krivak TC, Horowitz NS, Rodriguez N, Hamilton CA, Backes FJ, Carson LF, Friedlander M, Mutch DG, Goodheart MJ, Tewari KS, Wenham RM, Bookman MA, Maxwell GL, Richard SD. PMID: 27864921.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    61. Fifth annual workshop of cytoreductive surgery for advanced ovarian cancer and peritoneal surface malignancies. Gynecol Oncol Res Pract. 2016; 3:10. Tewari KS. PMID: 28685778.
      View in: PubMed   Mentions:
    62. Impact of histology and surgical approach on survival among women with early-stage, high-grade uterine cancer: An NRG Oncology/Gynecologic Oncology Group ancillary analysis. Gynecol Oncol. 2016 Dec; 143(3):460-465. Fader AN, Java J, Tenney M, Ricci S, Gunderson CC, Temkin SM, Spirtos N, Kushnir CL, Pearl ML, Zivanovic O, Tewari KS, O'Malley D, Hartenbach EM, Hamilton CA, Gould NS, Mannel RS, Rodgers W, Walker JL. PMID: 27743738.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    63. Does time interval between surgery and intraperitoneal chemotherapy administration in advanced ovarian cancer carry a prognostic impact? An NRG Oncology/Gynecologic Oncology Group study ancillary study. Gynecol Oncol. 2016 Dec; 143(3):484-489. Garcia-Soto AE, Java JJ, Nieves Neira W, Pearson JM, Cohn DE, Lele SB, Tewari KS, Walker JL, Alvarez Secord A, Armstrong DK, Copeland LJ. PMID: 27726923.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    64. Is age a prognostic biomarker for survival among women with locally advanced cervical cancer treated with chemoradiation? An NRG Oncology/Gynecologic Oncology Group ancillary data analysis. Gynecol Oncol. 2016 Nov; 143(2):294-301. Moore KN, Java JJ, Slaughter KN, Rose PG, Lanciano R, DiSilvestro PA, Thigpen JT, Lee YC, Tewari KS, Chino J, Seward SM, Miller DS, Salani R, Moore DH, Stehman FB. PMID: 27542967.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    65. Evaluation of the pharmacokinetics and metabolism of pembrolizumab in the treatment of melanoma. Expert Opin Drug Metab Toxicol. 2016 Oct; 12(10):1247-53. Longoria TC, Tewari KS. PMID: 27485741.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    66. Randomized Phase II Evaluation of Bevacizumab Versus Bevacizumab Plus Fosbretabulin in Recurrent Ovarian, Tubal, or Peritoneal Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study. J Clin Oncol. 2016 07 01; 34(19):2279-86. Monk BJ, Sill MW, Walker JL, Darus CJ, Sutton G, Tewari KS, Martin LP, Schilder JM, Coleman RL, Balkissoon J, Aghajanian C. PMID: 27217446.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCTClinical Trials
    67. Clinical Trials of Antiangiogenesis Therapy in Recurrent/Persistent and Metastatic Cervical Cancer. Oncologist. 2016 05; 21(5):576-85. Alldredge JK, Tewari KS. PMID: 27026677.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    68. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors. Curr Treat Options Oncol. 2016 Mar; 17(3):12. Liu FW, Tewari KS. PMID: 26931795.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCells
    69. Evolution of Chemosensitivity and Resistance Assays as Predictors of Clinical Outcomes in Epithelial Ovarian Cancer Patients. Curr Pharm Des. 2016; 22(30):4717-4728. Monk BJ, Herzog TJ, Tewari KS. PMID: 27145761.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    70. Recent Patents for Homologous Recombination Deficiency Assays Among Women with Ovarian Cancer. Recent Pat Biotechnol. 2016; 9(2):86-101. LaFargue CJ, Tewari KS. PMID: 26961668.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    71. Prospective Validation of Pooled Prognostic Factors in Women with Advanced Cervical Cancer Treated with Chemotherapy with/without Bevacizumab: NRG Oncology/GOG Study. Clin Cancer Res. 2015 Dec 15; 21(24):5480-7. Tewari KS, Sill MW, Monk BJ, Penson RT, Long HJ, Poveda A, Landrum LM, Leitao MM, Brown J, Reid TJ, Michael HE, Moore DH. PMID: 26672085.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCTClinical Trials
    72. A review of HER2-targeted therapy in breast and ovarian cancer: lessons from antiquity - CLEOPATRA and PENELOPE. Future Oncol. 2015; 11(23):3113-31. Hodeib M, Serna-Gallegos T, Tewari KS. PMID: 26597460.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    73. Pharmacologic management of advanced cervical cancer: antiangiogenesis therapy and immunotherapeutic considerations. Drugs. 2015 Nov; 75(16):1853-65. Longoria TC, Tewari KS. PMID: 26474780.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    74. Clinical implications for cediranib in advanced cervical cancer. Lancet Oncol. 2015 Nov; 16(15):1447-1448. Tewari KS. PMID: 26474520.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    75. Early initiation of chemotherapy following complete resection of advanced ovarian cancer associated with improved survival: NRG Oncology/Gynecologic Oncology Group study. Ann Oncol. 2016 Jan; 27(1):114-21. Tewari KS, Java JJ, Eskander RN, Monk BJ, Burger RA. PMID: 26487588.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCTClinical Trials
    76. Changing paradigms in the systemic treatment of advanced cervical cancer. Am J Obstet Gynecol. 2016 Jan; 214(1):22-30. Pfaendler KS, Tewari KS. PMID: 26212178.
      View in: PubMed   Mentions: 47     Fields:    Translation:Humans
    77. Development of Olaparib for BRCA-Deficient Recurrent Epithelial Ovarian Cancer. Clin Cancer Res. 2015 Sep 01; 21(17):3829-35. Tewari KS, Eskander RN, Monk BJ. PMID: 26169965.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    78. US FDA oncology drug approvals in 2014. Future Oncol. 2015; 11(13):1931-45. Wolford JE, Tewari KS. PMID: 26039742.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    79. Anti-angiogenesis therapy in gynecologic malignancies. Oncology (Williston Park). 2015 May; 29(5):350-60. Liu FW, Cripe J, Tewari KS. PMID: 25979545.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    80. Sentinel lymph node mapping of a breast cancer of the vulva: Case report and literature review. World J Clin Oncol. 2015 Apr 10; 6(2):16-21. Cripe J, Eskander R, Tewari K. PMID: 25866706.
      View in: PubMed   Mentions:
    81. A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2015 Jun; 137(3):386-91. Coleman RL, Sill MW, Bell-McGuinn K, Aghajanian C, Gray HJ, Tewari KS, Rubin SC, Rutherford TJ, Chan JK, Chen A, Swisher EM. PMID: 25818403.
      View in: PubMed   Mentions: 85     Fields:    Translation:HumansCTClinical Trials
    82. A Markov model to evaluate cost-effectiveness of antiangiogenesis therapy using bevacizumab in advanced cervical cancer. Gynecol Oncol. 2015 Jun; 137(3):490-6. Minion LE, Bai J, Monk BJ, Robin Keller L, Ramez EN, Forde GK, Chan JK, Tewari KS. PMID: 25766118.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    83. Novel MSH2 Mutation in the First Report of a Vietnamese-American Kindred with Lynch Syndrome. Gynecol Oncol Rep. 2015 Apr; 12:31-3. Eskander RN, Lynch HT, Brown SM, Wagman LD, Tewari KS. PMID: 26076155.
      View in: PubMed   Mentions:
    84. Reply to W.A.A. Tjalma and J.S. Grossman. J Clin Oncol. 2015 Mar 10; 33(8):966. Monk BJ, Miller DS, Tewari KS. PMID: 25667286.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    85. Integration of bevacizumab with chemotherapy doublets for advanced cervical cancer. Expert Opin Pharmacother. 2015 Apr; 16(5):675-83. Krill LS, Tewari KS. PMID: 25643984.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    86. Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240). Lancet Oncol. 2015 Mar; 16(3):301-11. Penson RT, Huang HQ, Wenzel LB, Monk BJ, Stockman S, Long HJ, Ramondetta LM, Landrum LM, Oaknin A, Reid TJ, Leitao MM, Method M, Michael H, Tewari KS. PMID: 25638326.
      View in: PubMed   Mentions: 40     Fields:    Translation:HumansCTClinical Trials
    87. Development of bevacizumab in advanced cervical cancer: pharmacodynamic modeling, survival impact and toxicology. Future Oncol. 2015; 11(6):909-22. Eskander RN, Tewari KS. PMID: 25760973.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    88. Exploring the therapeutic rationale for angiogenesis blockade in cervical cancer. Clin Ther. 2015 Jan 01; 37(1):9-19. Krill LS, Tewari KS. PMID: 25592088.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    89. Immunotherapy: an evolving paradigm in the treatment of advanced cervical cancer. Clin Ther. 2015 Jan 01; 37(1):20-38. Eskander RN, Tewari KS. PMID: 25592089.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    90. Development of a platform for systemic antiangiogenesis therapy for advanced cervical cancer. Clin Adv Hematol Oncol. 2014 Nov; 12(11):737-48. Tewari KS, Monk BJ. PMID: 25674713.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    91. Targeting angiogenesis in advanced cervical cancer. Ther Adv Med Oncol. 2014 Nov; 6(6):280-92. Eskander RN, Tewari KS. PMID: 25364393.
      View in: PubMed   Mentions:
    92. Impact of race, socioeconomic status, and the health care system on the treatment of advanced-stage ovarian cancer in California. Am J Obstet Gynecol. 2015 Apr; 212(4):468.e1-9. Long B, Chang J, Ziogas A, Tewari KS, Anton-Culver H, Bristow RE. PMID: 25448522.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    93. Exploiting the therapeutic potential of the PI3K-AKT-mTOR pathway in enriched populations of gynecologic malignancies. Expert Rev Clin Pharmacol. 2014 Nov; 7(6):847-58. Eskander RN, Tewari KS. PMID: 25301678.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimals
    94. Updates on drug discovery in ovarian cancer. Gynecol Oncol Res Pract. 2014; 1:3. Gibson SJ, Tewari KS, Monk BJ, Chase DM. PMID: 27231556.
      View in: PubMed   Mentions:
    95. Pathologic findings at risk-reducing salpingo-oophorectomy: primary results from Gynecologic Oncology Group Trial GOG-0199. J Clin Oncol. 2014 Oct 10; 32(29):3275-83. Sherman ME, Piedmonte M, Mai PL, Ioffe OB, Ronnett BM, Van Le L, Ivanov I, Bell MC, Blank SV, DiSilvestro P, Hamilton CA, Tewari KS, Wakeley K, Kauff ND, Yamada SD, Rodriguez G, Skates SJ, Alberts DS, Walker JL, Minasian L, Lu K, Greene MH. PMID: 25199754.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCTClinical Trials
    96. New strategies in advanced cervical cancer: from angiogenesis blockade to immunotherapy. Clin Cancer Res. 2014 Nov 01; 20(21):5349-58. Tewari KS, Monk BJ. PMID: 25104084.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansAnimalsCells
    97. Chemotherapy in the treatment of metastatic, persistent, and recurrent cervical cancer. Curr Opin Obstet Gynecol. 2014 Aug; 26(4):314-21. Eskander RN, Tewari KS. PMID: 24979076.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansPHPublic Health
    98. Evidence-based therapy for recurrent cervical cancer. J Clin Oncol. 2014 Sep 01; 32(25):2687-90. Monk BJ, Tewari KS. PMID: 25071120.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    99. Pemetrexed and cisplatin for the treatment of advanced, persistent, or recurrent carcinoma of the cervix: a limited access phase II trial of the gynecologic oncology group. J Clin Oncol. 2014 Sep 01; 32(25):2744-9. Miller DS, Blessing JA, Ramondetta LM, Pham HQ, Tewari KS, Landrum LM, Brown J, Mannel RS. PMID: 25071133.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    100. Beyond angiogenesis blockade: targeted therapy for advanced cervical cancer. J Gynecol Oncol. 2014 Jul; 25(3):249-59. Eskander RN, Tewari KS. PMID: 25045438.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    101. PARP inhibition and synthetic lethality in ovarian cancer. Expert Rev Clin Pharmacol. 2014 Sep; 7(5):613-22. Eskander RN, Tewari KS. PMID: 24984781.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    102. Use of stereotactic radiosurgery in the treatment of gynecologic malignancies: A review. World J Radiol. 2014 Jun 28; 6(6):366-73. Long B, Eskander RN, Tewari KS. PMID: 24976937.
      View in: PubMed   Mentions:
    103. Assessment of palliative care training in gynecologic oncology: a gynecologic oncology fellow research network study. Gynecol Oncol. 2014 Aug; 134(2):379-84. Eskander RN, Osann K, Dickson E, Holman LL, Rauh-Hain JA, Spoozak L, Wu E, Krill L, Fader AN, Tewari KS. PMID: 24887355.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    104. New world order(s): healthcare metrics, international borders, and gravitational waves. Gynecol Oncol. 2014 May; 133(2):139-41. Tewari KS. PMID: 24773670.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    105. Chemotherapy-induced neutropenia as a biomarker of survival in advanced ovarian carcinoma: an exploratory study of the gynecologic oncology group. Gynecol Oncol. 2014 Jun; 133(3):439-45. Tewari KS, Java JJ, Gatcliffe TA, Bookman MA, Monk BJ. PMID: 24657300.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    106. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med. 2014 Feb 20; 370(8):734-43. Tewari KS, Sill MW, Long HJ, Penson RT, Huang H, Ramondetta LM, Landrum LM, Oaknin A, Reid TJ, Leitao MM, Michael HE, Monk BJ. PMID: 24552320.
      View in: PubMed   Mentions: 343     Fields:    Translation:HumansCTClinical Trials
    107. American Society of Clinical Oncology 2013: summary of scientific advancements in gynecologic cancer. Int J Gynecol Cancer. 2014 Jan; 24(1):13-8. Eskander RN, Tewari KS. PMID: 24300468.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    108. Incorporation of anti-angiogenesis therapy in the management of advanced ovarian carcinoma--mechanistics, review of phase III randomized clinical trials, and regulatory implications. Gynecol Oncol. 2014 Feb; 132(2):496-505. Eskander RN, Tewari KS. PMID: 24316305.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    109. Methylation of human papillomavirus 16, 18, 31, and 45 L2 and L1 genes and the cellular DAPK gene: Considerations for use as biomarkers of the progression of cervical neoplasia. Virology. 2014 Jan 05; 448:314-21. Kalantari M, Osann K, Calleja-Macias IE, Kim S, Yan B, Jordan S, Chase DM, Tewari KS, Bernard HU. PMID: 24314662.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCells
    110. Epithelial cell-adhesion molecule-directed trifunctional antibody immunotherapy for symptom management of advanced ovarian cancer. Clin Pharmacol. 2013 Oct 03; 5(Suppl 1):55-61. Eskander RN, Tewari KS. PMID: 24124397.
      View in: PubMed   Mentions:
    111. Impact of a multivariate index assay on referral patterns for surgical management of an adnexal mass. Am J Obstet Gynecol. 2013 Dec; 209(6):581.e1-8. Bristow RE, Hodeib M, Smith A, Chan DW, Zhang Z, Fung ET, Tewari KS, Munroe DG, Ueland FR. PMID: 23942039.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    112. Toll-like receptor 8: augmentation of innate immunity in platinum resistant ovarian carcinoma. Clin Pharmacol. 2013; 5:13-9. Brueseke TJ, Tewari KS. PMID: 23723721.
      View in: PubMed   Mentions:
    113. Outside slide review in gynecologic oncology: impact on patient care and treatment. Int J Gynecol Pathol. 2013 May; 32(3):293-8. Eskander RN, Baruah J, Nayak R, Brueseke T, Ji T, Wardeh R, Tewari KS. PMID: 23518913.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    114. A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2013 Jun; 129(3):486-94. Leslie KK, Sill MW, Fischer E, Darcy KM, Mannel RS, Tewari KS, Hanjani P, Wilken JA, Baron AT, Godwin AK, Schilder RJ, Singh M, Maihle NJ. PMID: 23438670.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCellsCTClinical Trials
    115. Advanced cytoreductive surgery workshop report. Int J Gynecol Cancer. 2012 Nov; 22(9):1604-10. Tewari KS. PMID: 23095776.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    116. American Society of Clinical Oncology 2012 Annual Meeting: highlights from the gynecologic oncology track. Int J Gynecol Cancer. 2012 Nov; 22(9):1634-9. Tewari KS. PMID: 23095779.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    117. The challenge of follow-up in a low-income colposcopy clinic: characteristics associated with noncompliance in high-risk populations. J Low Genit Tract Dis. 2012 Oct; 16(4):345-51. Chase DM, Osann K, Sepina N, Wenzel L, Tewari KS. PMID: 22622340.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    118. Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer. Gynecol Oncol. 2012 Nov; 127(2):345-50. Leslie KK, Sill MW, Lankes HA, Fischer EG, Godwin AK, Gray H, Schilder RJ, Walker JL, Tewari K, Hanjani P, Abulafia O, Rose PG. PMID: 22885469.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCTClinical Trials
    119. Emerging treatment options for management of malignant ascites in patients with ovarian cancer. Int J Womens Health. 2012; 4:395-404. Eskander RN, Tewari KS. PMID: 22927770.
      View in: PubMed   Mentions:
    120. Outcomes of high-dose-rate interstitial brachytherapy in the treatment of locally advanced cervical cancer: long-term results. Int J Radiat Oncol Biol Phys. 2013 Mar 01; 85(3):714-20. Pinn-Bingham M, Puthawala AA, Syed AM, Sharma A, Disaia P, Berman M, Tewari KS, Randall-Whitis L, Mahmood U, Ramsinghani N, Kuo J, Chen WP, McLaren CE. PMID: 22763030.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    121. Role of canonical Wnt signaling in endometrial carcinogenesis. Expert Rev Anticancer Ther. 2012 Jan; 12(1):51-62. Dellinger TH, Planutis K, Tewari KS, Holcombe RF. PMID: 22149432.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansAnimalsCells
    122. Association of number of positive nodes and cervical stroma invasion with outcome of advanced endometrial cancer treated with chemotherapy or whole abdominal irradiation: a Gynecologic Oncology Group study. Gynecol Oncol. 2012 Apr; 125(1):87-93. Tewari KS, Filiaci VL, Spirtos NM, Mannel RS, Thigpen JT, Cibull ML, Monk BJ, Randall ME. PMID: 22155678.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    123. American Society of Clinical Oncology 2011 Annual Meeting update: summary of selected gynecologic cancer abstracts. Gynecol Oncol. 2011 Aug; 122(2):209-12. Tewari KS, Monk BJ. PMID: 21763890.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    124. Fertility preserving options in patients with gynecologic malignancies. Am J Obstet Gynecol. 2011 Aug; 205(2):103-10. Eskander RN, Randall LM, Berman ML, Tewari KS, Disaia PJ, Bristow RE. PMID: 21411052.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    125. Drug discovery in ovarian cancer. Recent Pat Anticancer Drug Discov. 2010 Nov; 5(3):251-60. Chase DM, Mathur N, Tewari KS. PMID: 20524931.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    126. A phase 2 evaluation of irofulven as second-line treatment of recurrent or persistent intermediately platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group trial. Int J Gynecol Cancer. 2010 Oct; 20(7):1137-41. Schilder RJ, Blessing JA, Shahin MS, Miller DS, Tewari KS, Muller CY, Warshal DP, McMeekin S, Rotmensch J. PMID: 21495215.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    127. Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): A Gynecologic Oncology Group Study. Gynecol Oncol. 2010 Dec; 119(3):444-50. Hurteau JA, Brady MF, Darcy KM, McGuire WP, Edmonds P, Pearl ML, Ivanov I, Tewari KS, Mannel RS, Zanotti K, Benbrook DM. PMID: 20846715.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCTClinical Trials
    128. The rationale for the use of non-platinum chemotherapy doublets for metastatic and recurrent cervical carcinoma. Clin Adv Hematol Oncol. 2010 Feb; 8(2):108-15. Tewari KS, Monk BJ. PMID: 20386532.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    129. Recombination of human papillomavirus-16 and host DNA in exfoliated cervical cells: a pilot study of L1 gene methylation and chromosomal integration as biomarkers of carcinogenic progression. J Med Virol. 2010 Feb; 82(2):311-20. Kalantari M, Chase DM, Tewari KS, Bernard HU. PMID: 20029805.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCells
    130. Socioeconomic factors may contribute to neoadjuvant chemotherapy use in metastatic epithelial ovarian carcinoma. Gynecol Oncol. 2009 Dec; 115(3):339-42. Chase DM, Rincon A, Deane M, Tewari KS, Brewster WR. PMID: 19772939.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    131. Beyond platinum for metastatic and recurrent carcinoma of the cervix. Onkologie. 2009 Oct; 32(10):552-4. Tewari KS, Monk BJ. PMID: 19816070.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    132. Pelvic radiation improves local control after hysterectomy for uterine leiomyosarcoma: a 20-year experience. Int J Gynecol Cancer. 2009 Aug; 19(6):1080-4. Mahdavi A, Monk BJ, Ragazzo J, Hunter MI, Lentz SE, Vasilev SA, Tewari KS. PMID: 19820372.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    133. Recent achievements and future developments in advanced and recurrent cervical cancer: trials of the Gynecologic Oncology Group. Semin Oncol. 2009 Apr; 36(2):170-80. Tewari KS, Monk BJ. PMID: 19332251.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    134. Green tea catechins for treatment of external genital warts. Am J Obstet Gynecol. 2009 Mar; 200(3):233.e1-7. Meltzer SM, Monk BJ, Tewari KS. PMID: 19019336.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansAnimals
    135. A feasibility study of topotecan with standard-dose cisplatin and concurrent primary radiation therapy in locally advanced cervical cancer. Gynecol Oncol. 2009 Jan; 112(1):85-9. Gatcliffe TA, Tewari KS, Shah A, Brewster WR, Burger RA, Kuo JV, Monk BJ. PMID: 18977518.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    136. The influence of conservative surgical practices for malignant ovarian germ cell tumors. J Surg Oncol. 2008 Aug 01; 98(2):111-6. Chan JK, Tewari KS, Waller S, Cheung MK, Shin JY, Osann K, Kapp DS. PMID: 18563734.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    137. Cervical neoplasia in pregnancy. Part 2: current treatment of invasive disease. Am J Obstet Gynecol. 2008 Jul; 199(1):10-8. Hunter MI, Tewari K, Monk BJ. PMID: 18585521.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    138. Cervical neoplasia in pregnancy. Part 1: screening and management of preinvasive disease. Am J Obstet Gynecol. 2008 Jul; 199(1):3-9. Hunter MI, Monk BJ, Tewari KS. PMID: 18585520.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansPHPublic Health
    139. Supportive care for women with gynecologic cancers. Expert Rev Anticancer Ther. 2008 Feb; 8(2):227-41. Chase DM, Monk BJ, Wenzel LB, Tewari KS. PMID: 18279064.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    140. The spectrum and clinical sequelae of human papillomavirus infection. Gynecol Oncol. 2007 Nov; 107(2 Suppl 1):S6-13. Monk BJ, Tewari KS. PMID: 18499914.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    141. Multimodality therapy for locally advanced cervical carcinoma: state of the art and future directions. J Clin Oncol. 2007 Jul 10; 25(20):2952-65. Monk BJ, Tewari KS, Koh WJ. PMID: 17617527.
      View in: PubMed   Mentions: 57     Fields:    Translation:Humans
    142. Gynecologic oncology group trials of chemotherapy for metastatic and recurrent cervical cancer. Curr Oncol Rep. 2005 Nov; 7(6):419-34. Tewari KS, Monk BJ. PMID: 16221379.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    143. Conservation of in vitro drug resistance patterns in epithelial ovarian carcinoma. Gynecol Oncol. 2005 Sep; 98(3):360-8. Tewari KS, Mehta RS, Burger RA, Yu IR, Kyshtoobayeva AS, Monk BJ, Manetta A, Berman ML, Disaia PJ, Fruehauf JP. PMID: 16000215.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    144. Surgical cytoreduction and hormone therapy of an advanced endometrial stromal sarcoma of the ovary. Obstet Gynecol. 2004 May; 103(5 Pt 2):1051-4. Geas FL, Tewari DS, Rutgers JK, Tewari KS, Berman ML. PMID: 15121605.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    145. Unusual presentation of a malignant granular cell tumor of the pelvis: case report and literature review. Gynecol Oncol. 2003 Jul; 90(1):224-30. Berg JC, Tewari KS, Del Rosario R, Berman ML. PMID: 12821371.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    146. Primary prevention of uterine cervix cancer: focus on vaccine history and current strategy. Obstet Gynecol Clin North Am. 2002 Dec; 29(4):843-68, ix. Tewari KS, DiSaia PJ. PMID: 12509098.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    147. Long-term results of low-dose-rate interstitial-intracavitary brachytherapy in the treatment of carcinoma of the cervix. Int J Radiat Oncol Biol Phys. 2002 Sep 01; 54(1):67-78. Syed AM, Puthawala AA, Abdelaziz NN, el-Naggar M, Disaia P, Berman M, Tewari KS, Sharma A, Londrc A, Juwadi S, Cherlow JM, Damore S, Chen YJ. PMID: 12182976.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    148. Lung and bronchus cancer in women: a 21st-century epidemic. Clin Obstet Gynecol. 2002 Sep; 45(3):784-811. Tewari KS, Disaia PJ. PMID: 12370622.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    149. Radiation therapy for gynecologic cancer. J Obstet Gynaecol Res. 2002 Jun; 28(3):123-40. Tewari KS, DiSaia PJ. PMID: 12214828.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    150. Treatment of recurrent gynecologic malignancies with iodine-125 permanent interstitial irradiation. Int J Radiat Oncol Biol Phys. 2002 Mar 01; 52(3):806-15. Monk BJ, Tewari KS, Puthawala AA, Syed AM, Haugen JA, Burger RA. PMID: 11849805.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    Krishnansu's Networks
    Concepts (381)
    Derived automatically from this person's publications.
    _
    Co-Authors (22)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _